• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Why Roux-en-Y Gastric Bypass Remains the Gold Standard in Bariatric Surgery

Video

Roux-en-Y gastric bypass remains the gold standard of bariatric surgery. Obesity and nutrition expert Caroline Apovian, MD, explains why and how it differs from the 3 other types of weight loss surgery.

Obesity and nutrition expert Caroline Apovian, MD, explains the 4 types of bariatric surgery, the essential differences in how each affects levels of regulatory peptides that communicate satiety to the brain, and why Roux-en-Y gastric bypass remains the gold standard.

_______________________________

Caroline M. Apovian, MD, is professor of medicine and pediatrics, in the section of endocrinology, diabetes, and nutrition at Boston University School of Medicine and the director of the Center for Nutrition and Weight Management at Boston Medical Center.

Bariatric surgery, Roux-en-Y gastric bypass, Caroline Apovian, MD

Caroline Apovian, MD

Dr. Apovian is an internationally recognized authority on nutrition, metabolism, and obesity medicine and has been in the field for nearly 3 decades.

Her current research interests are in: weight loss/gain and its effects on adipose tissue metabolism and inflammation, obesity and cardiovascular disease (CVD), resolution of diabetes and CVD in the bariatric surgery population, disparities in the treatment of obesity in underserved populations and novel pharmacotherapeutic agents for the treatment of obesity.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.